

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OUTSIDE INDIA Initial Public Offer of equity shares on the main board of BSE Limited ("BSE") and National Stock Exchange of India Limited ("SEBI ICDR Regulations")



Please scan this QR Code to view the Prospectus)

Cumulative unique dental

network developed

between Fiscal 2022 to

Fiscal 2024

22,000+\*

Our Company was incorporated as 'Laxmi Dental Export Private Limited' as a private limited company under the Companies Act, 1956 pursuant to a certificate of incorporation dated July 8, 2004, issued by the Assistant Registrar of Companies, Maharashtra at Mumbai. Pursuant to a special resolution passed in the extra-ordinary general meeting of our Shareholders held on June 18, 2024, the name of our Company was changed to 'Laxmi Dental Private Limited', and a fresh certificate of incorporation was issued to our Company by the RoC on July 24, 2024, and our Company was converted into a public limited company. Consequently, the name of our Company was further changed to 'Laxmi Dental Limited', and a fresh certificate of incorporate Matters' on page 328 of the Property.

Registered Office: Office No. 103, Akruti Arcade, J. P. Road, Opposite A.H. Wadia High School, Andheri (West), Mumbai – 400 058, Maharashtra, India; Tel: +91 22 6143 7991 Corporate Office: 301, A-wing, Interface-16, Mindspace, Malad (West), Mumbai – 400 064, Maharashtra, India; Tel: +91 22 6143 7992; Contact Person: Nupur Joshi, Company Secretary and Compliance Officer; E-mail: co.sec@laxmidentallimited.com; Website: www.laxmidentallimited.com; Websit

## PROMOTERS OF OUR COMPANY: RAJESH VRAJLAL KHAKHAR, SAMEER KAMLESH MERCHANT AND DHARMESH BHUPENDRA DATTANI

Our Company has filed the prospectus dated January 16, 2025 with the RoC (the "Prospectus") and the Equity Shares (as defined below) are proposed to be listed on the Main Board of the Stock Exchanges and the trading will commence on Monday, January 20, 2025.

# **BASIS OF ALLOTMENT**

INITIAL PUBLIC OFFERING OF 16,309,766 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY") OF LAXMI DENTAL LIMITED (OUR "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹428 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹426 PER EQUITY SHARE (THE "OFFER PRICE") AGGREGATING TO ₹6,980.58 MILLION (THE "OFFER"). THE OFFER COMPRISES OF A FRESH ISSUE OF 3,224,299 EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY OUR COMPANY AGGREGATING TO ₹1,330 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF 13,085,467 EQUITY SHARES OF FACE VALUE OF ₹2 EACH (THE "OFFERE SHARES") AGGREGATING TO ₹6,980.58 MILLION (THE "OFFER FOR SALE"), COMPRISING OT ₹1,330 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF 13,085,467 EQUITY SHARES OF FACE VALUE OF ₹2 EACH (THE "OFFERE SHARES") AGGREGATING TO ₹6,0.58MILLION (THE "OFFER FOR SALE"), COMPRISING OF 196,604 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹84.15 MILLION BY RAJES VRAJLAL KHAKHAR, 434,598 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹186.00 MILLION BY SAMEER KAMLESH MERCHANT (TOGETHER THE "PROMOTER SELLING SHAREHOLDERS"), 239,838 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹64.22 MILLION BY RAJES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹64.22 MILLION BY AMRISH MAHENDRABHAI DESAI, 150,040 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹64.22 MILLION BY PARAG JAMNADAS BHIMJIYANI, 150,040 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹64.22 MILLION BY PARAG JAMNADAS BHIMJIYANI, 150,040 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹64.22 MILLION BY KUNAL KAMLESH MERCHANT (TOGETHER THE "OTHER SELLING SHAREHOLDERS"), 11,614,267 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹4,970.91MILLION BY ORBIMED ASIA II MAURTIUS LIMITED (THE "INVESTOR SELLING SHAREHOLDER") (THE PROMOTER SELLING SHAREHOLDERS"). THE INVESTOR SELLING SHAREHOLDER AND THE OTHER SELLING SHAREHOLDERS.) COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") (THE "OFFER FOR SALE, AND TOGETHER WITH THE FRESH I

# ANCHOR INVESTOR OFFER PRICE: ₹ 428 PER EQUITY SHARE OF FACE VALUE OF ₹ 2 EACH OFFER PRICE: ₹ 428 PER EQUITY SHARE OF FACE VALUE OF ₹ 2 EACH THE OFFER PRICE IS 214 TIMES THE FACE VALUE OF THE EQUITY SHARES.

## **RISK TO INVESTORS**

## For details please refer to section titled "Risk Factors" on page 37 of the Prospectus

Particulars

**Dental Network** 

1. Our Company has reported consolidated loss after tax, negative earning per share for Fiscals 2023 and 2022, and written off Assets in last three Fiscals and we cannot assure that we will not experience such events in the future. Further, we have experienced negative cash flows from operating activities in the past and may continue to do so in the future:

achieve this in a cost-effective manner could have an adverse effect on our business, results of operations and financial condition. Further, lack of long-term purchase orders or commitments from Dental Network increases the risk of pricing pressure from our Dental Network which may have an adverse effect on our business, operations and financial condition. Details of dental network is as follows:

11,000+

Fiscal 2022

10,400+

Fiscal 2024 Fiscal 2023

12,200+

Particulars	Six month period ended September 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
Restated profit/ (loss) (in ₹ million)	227.39	252.29	(41.63)	(186.79)
Write-offs	1.63	4.65	0.65	7.40

Business Risk - Our business success depends on expanding our Dental Network, recommendations by our Dental Network and increasing the wallet share per dental clinic, dental company and dentist. Failure to

The majority of our revenues from the B2B2C model, which involves the sale of our dental products to end customers through our Dental Network.

Six month period ended September 30, 2024		Fiscal 20	024	Fiscal 20	023	Fiscal 20	22
Total revenue from goods and services from the B2B2C model (in ₹ million)	% of our total revenue from sale of goods and services		% of our total revenue from sale of goods and services	Total revenue from goods and services from the B2B2C model (in ₹ million)		Total revenue from goods and services from the B2B2C model (in ₹ million)	% of our total revenue from sale of goods and services
952.49	82.34%	1,596.88	83.41%	1,233.41	77.60%	980.32	75.71%
3. Supplier Concentration a	3. Supplier Concentration and Pricing Risk - Our lack of long-term supply orders of key raw materials and components from our suppliers increases the risk of pricing pressure for our demand of continued supply, any variation in the supply						

and cost of such key raw materials and traded goods could have an adverse effect on our business, financial condition and operations.

	Six month period ended September 30, 2024			Fiscal 2024		Fiscal 2023		Fiscal 2022	
Particular	Amount (in ₹ million)	As a % of the cost of total raw materials and traded goods purchased	Amount (in ₹ million)	As a % of the cost of total raw materials and traded goods purchased	Amount (in ₹ million)	As a % of the cost of total raw materials and traded goods purchased	Amount (in ₹ million)	As a % of the cost of total raw materials and traded goods purchased	
Top 5 Suppliers*	94.08	34.88%	180.93	35.45%,	165.72	42.92%	122.54	28.69%	
Top 10 Suppliers*	134.58	49.89%	272.09	54.24%	224.87	58.24%	191.02	44.72%	

\* We are not in a position to disclose the names of our top 5 and top 10 suppliers as this is commercially sensitive information. The top 5 and top 10 suppliers may vary for each Fiscal as per actuals.

4. <u>Geographical Concentration Risk</u> - Our business is concentrated in certain jurisdictions, globally and domestically, and any loss of business in such regions could have an adverse effect on our business, results of operations and financial condition. Details of It is given as, revenue from sale of goods and services' in Prospectus in various zones are as follows: (in ₹ million)

Particulars	For the six month period ended September 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
India	780.94	1,291.58	1,088.20	754.61
USA	220.70	371.68	295.34	367.23
UK	84.76	137.48	115.96	81.15
Others	70.39	113.76	89.91	91.79
Total	1,156.79	1,914.50	1,589.41	1,294.78

5. Our business depends heavily on our reputation and perception of our brands. Any negative publicity or other harm to our brand or failure to maintain and enhance our brand recognition and maintain such quality standards may materially and adversely affect our reputation, business, results of operations and financial condition.

Particulars	Six month period ended September 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
Total Units sold from manufacturing facilities in Mumbai Metropolitan Region	18,40,650	32,85,370	22,78,947	27,99,328
% of Total Units from Mumbai Metropolitan Region	98.59%	98.88%	98.78%	99.60%
Overall Total Units Sold	18,67,054	33,22,660	23,07,149	28,10,641

\* Consists of units sold by Kids-E-Dental LLP, our Jointly Controlled Entity.

Six month

period ended

September 30,

2024

9,500+

\*After adjusting for repeat member to the Dental Network in the subsequent years.

 Legal Risk - There are outstanding legal proceedings involving our Company, Subsidiaries, Promoters, and Directors which could have an adverse effect on our business, financial condition and results of operations.

8. <u>Forex Risk</u> - Import and Exports are material to our business operation. Further, a failure to manage our business in overseas markets or our inability to grow our business in new geographic markets may affect our growth, which could have a material adverse effect on our business, operations, prospects or financial condition. Details of total export revenue is below: (in ₹ million)

6. <u>Manufacturing location Risk</u> - Five out of six of our key manufacturing facilities are situated in and around Mumbai and any disruptions in the region could have a material and adverse effect on our business, financial condition and results of operations. Details of total units sold is below:

Particulars	Six month period ended September 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
Laboratory Division	3,81,209	6,13,960	5,20,959	4,95,203
Aligner and Aligner Products Division	10,14,083	21,32,772	16,71,649	22,81,993
Paediatric Division*	4,45,358	538,638	86,339	22,132

There have been instances where the import of raw materials was halted by relevant authorities, disrupting our supply chain and potentially leading to delays in production and increased costs. (in ₹ million)

Particulars	Six month period ended September 30, 2024	For Fiscal 2024	For Fiscal 2023	For Fiscal 2022
Total purchase value of import of goods (raw materials and traded goods)	120.20	258.53	240.82	239.60
Total cost of goods sold ("COGS")*	282.55	484.89	417.98	396.55
Total purchase value of import of goods as a % to COGS	42.54%	53.32%	57.61%	60.42%

\*Cost of goods sold = Cost of material consumed + Purchase of stock-in-trade + Change in inventories of finished goods.

- Regulatory Risk Our dental products are subject to extensive and dynamic regulations and any non-compliance with and changes in any of the applicable laws, rules or regulations related to the manufacturing, selling or distribution of our dental products, may adversely affect our business, results of operations and financial condition and cash flows.
- 10. <u>Employee Attrition related Risk</u> Our business is heavily reliant on a number of qualified and experienced dental technicians and skilled laboratory staff, and any failure to attract, retain, or manage these personnel effectively could have an adverse impact on business, operations and financial condition. The attrition rates for our dental technicians and skilled laboratory staff for the six month period ended September 30, 2024 and the Fiscal 2024, 2023, and 2022 were 13.44%, 18.23%, 27.32%, and 29.77%, respectively
- 11. Changes in public healthcare schemes or the fluctuation of the dental insurance coverage in U.S. and the UK regions could result in an adverse impact on our business, operations, financial condition, performance and growth prospect.

## 12 Market Risk :

The determination of the Price Band is based on various factors and assumptions and the Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares after the Offer. Further, the current market price of some securities listed pursuant to certain previous issues managed by the BRLM is below their respective issue prices. The Offer Price of our Equity Shares, our market capitalization to Total Income and our Price to Earning ratio at Offer Price may not be indicative of the market price of the Equity Shares after the Offer.

Particulars	Ratio vis-à-vis Floor Price (₹ 407)	Ratio vis-à-vis Cap Price (₹ 428)
Market capitalization to total income (based on Fiscal 2024) and calculated on Pre Issue Shares	10.78	11.34
Price to Earning (Diluted) (based on Fiscal 2024)	79.65	83.76
Price to Book Value (based on September 30, 2024)	31.39	33.01

Particulars	Six month period ended September 30, 2024	Fiscal 2024	Fiscal 2023	Fiscal 2022
U.S.	220.70	371.68	295.34	367.23
UK	84.76	137.48	115.96	81.15
Others	70.39	113.76	89.91	91.79
Total Export Revenue	375.85	622.92	501.21	540.17

13. The Weighted Average Cost of Acquisition of all Equity Shares transacted in last three years, 18 months and one year preceding the date of the Prospectus:

Period	Weighted average cost of acquisition ("WACA") (in ₹)*	Lower End of the Price Band is 'X' times the WACA^	Price Band is 'X'	Range of acquisition price Lowest Price - Highest Price (in ₹)*
Last three years	23.57	17.27	18.16	NIL <sup>@</sup> -145.47
Last 18 months	26.63	15.28	16.07	26.12-145.47
Last one year	26.63	15.28	16.07	26.12-145.47

\*As certified by NBT and Co, Chartered Accountants, pursuant to their certificate dated January 07, 2025.

<sup>®</sup>On Account of transmission of equity shares

^To be updated in Prospectus following the finalisation of the Price Band.

14. Weighted average cost of acquisition compared to Floor Price and Cap Price:

Past transactions	Weighted average cost of acquisition per Equity Share (₹) <sup>#</sup>	Floor Price (₹)*	Cap Price (₹)*
WACA of Equity Shares based on primary issuances undertaken during the three immediately preceding years	N.A.	N.A.	N.A.
WACA of Equity Shares based on secondary transactions undertaken during the three immediately preceding years	N.A.	N.A.	N.A.

<sup>#</sup> As certified by N B T and Co, Chartered Accountants by way of their certificate dated January 07, 2025.

15. The three BRLMs associated with the Offer have handled 75 public issues in the past three Financial Years, out of which 23 issues closed below the Offer price on the listing date.

Name of BRLMs	Total Public Issues	Issues Closed below the Offer Price on Listing Date
Nuvama Wealth Management Limited	25	7
Motilal Oswal Investment Advisors Limited	10	1
SBI Capital Markets Limited	31	9
Common Issues Handled by the BRLMs	9	6
Total	75	23

# BID/OFFER PROGRAMME: ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: FRIDAY, JANUARY 10, 2025 BID/OFFER OPENED ON : MONDAY, JANUARY 13, 2025 BID/OFFER CLOSED ON : WEDNESDAY, JANUARY 15, 2025

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Offer shall be allocated on a proportionate basis to the Qualified Institutional Buyers ("QIBs") ("QIB Portion"), provided that our Company in consultation with the BRLMs, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which at least one-third shall be reserved for domestic Mutual Funds, subject to valid Bids having been received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion (excluding the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion was made available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIBs other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not more than 15% of the Offer was made available for allocation to Non-Institutional Investors of which (a) one-third of such portion was reserved for applicants with application size of more than ₹200,000 and up to ₹1,000,000; and (b) two-third of such portion was reserved for applicants with application size of more than ₹1,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Offer was made available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received at or above the Offer Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID (in case of UPI Bidders) if applicable, in which the corresponding Bid Amounts were blocked by the SCSBs or by the Sponsor Bank(s) under the UPI Mechanism, as applicable, to the extent of the respective Bid Amounts. Anchor Investors were not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" beginning on page 544 of the Prospectus.

The bidding for Anchor Investor opened and closed on Friday, January 10, 2025. The company received 31 applications from 24 anchor investors for 7,806,249 equity shares. The Anchor investor price was finalized at ₹428 per Equity Share. A total of 7,339,395 shares were allocated under the Anchor Investor Portion aggregating to ₹3,141,261,060.00

The Offer received 3,293,340 applications for 1,028,541,921 Equity Shares (prior to rejections) resulting in 114.66 times subscription The details of the applications received in the Offer from various categories are as under: (before rejections):

SI. No.	Category	No. of Applications received	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
А	Retail Individual Investors	3,005,463	125,642,913	1,630,976	77.04	53,774,781,654.00
В	Non-Institutional Investors - More than ₹0.20 million Up to ₹1.00 million	173,806	89,824,812	815,488	110.15	38,443,385,937.00
С	Non-Institutional Investors - Above ₹1.00 million	113,909	274,839,510	1,630,976	168.51	117,630,613,485.00
D	Qualified Institutional Bidders (excluding Anchors Investors)	162	538,234,686	4,892,931	110.00	230,364,445,608.00
	Total	3,293,340	1,028,541,921	8,970,371	114.66	440,213,226,684.00

Final Demand

A summary of the final demand as at different Bid prices is as under:

Sr. No.	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	407	240,669	0.02	240,669	0.02
2	408	31,449	0.00	272,118	0.03
3	409	3,531	0.00	275,649	0.03
4	410	54,483	0.01	330,132	0.03
5	411	13,926	0.00	344,058	0.03
6	412	3,432	0.00	347,490	0.03
7	413	2,277	0.00	349,767	0.03
8	414	5,577	0.00	355,344	0.03
9	415	42,042	0.00	397,386	0.04
10	416	16,269	0.00	413,655	0.04
11	417	8,349	0.00	422,004	0.04
12	418	19,833	0.00	441,837	0.04
13	419	5,742	0.00	447,579	0.04
14	420	77,847	0.01	525,426	0.05
15	421	8,712	0.00	534,138	0.05
16	422	6,567	0.00	540,705	0.05
17	423	17,754	0.00	558,459	0.05
18	424	12,441	0.00	570,900	0.05
19	425	61,116	0.01	632,016	0.06
20	426	170,313	0.02	802,329	0.08
21	427	230,868	0.02	1,033,197	0.10
22	428	929,960,526	88.35	930,993,723	88.44
23	CUT-OFF	121,641,564	11.56	1,052,635,287	100.00
	TOTAL	1,052,635,287	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on Thursday, January 16, 2025.

#### A. Allotment to Retail Individual Investors (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at the Cut-Off Price or at the Offer Price of ₹428 per Equity Share, was finalized in consultation with the BSE. This category has been subscribed to the extent of 75.34 times. The total number of Equity Shares Allotted in Retail Portion is 1,630,976 Equity Shares to 49,423 successful Retail Individual Bidders. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
1	33	2,686,659	91.30	88,659,747	72.15	33	9:536	1,489,059
2	66	128,656	4.37	8,491,296	6.91	33	9:536	71,313
3	99	45,009	1.53	4,455,891	3.63	33	9:536	24,948
4	132	18,782	0.64	2,479,224	2.02	33	9:536	10,395
5	165	16,003	0.54	2,640,495	2.15	33	9:536	8,877
6	198	6,654	0.23	1,317,492	1.07	33	9:536	3,696
7	231	7,516	0.26	1,736,196	1.41	33	9:536	4,158
8	264	4,051	0.14	1,069,464	0.87	33	9:536	2,244
9	297	2,477	0.08	735,669	0.60	33	9:536	1,386
10	330	6,147	0.21	2,028,510	1.65	33	9:536	3,399
11	363	1,680	0.06	609,840	0.50	33	9:536	924
12	396	1,194	0.04	472,824	0.38	33	9:536	660
13	429	2,388	0.08	1,024,452	0.83	33	9:536	1,320
14	462	15,513	0.53	7,167,006	5.83	33	9:536	8,580
15		4,300 Allottees f	rom Serial no	2 to 14 Additional 1	(one) share	1	17:4300	17
	TOTAL	29,42,729	100.00	122,888,106	100.00			1,630,976

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
24	1,485	120	0.07	178,200	0.20	497	1:120	497
25	1,650	82	0.05	135,300	0.15	497	1:82	497
26	1,980	102	0.06	201,960	0.23	497	1:102	497
27	2,310	291	0.17	672,210	0.76	497	3:291	1,491
28	1,221	24	0.01	29,304	0.03	497	0:24	C
29	1,254	21	0.01	26,334	0.03	497	0:21	C
30	1,287	29	0.02	37,323	0.04	497	0:29	C
31	1,353	13	0.01	17,589	0.02	497	0:13	0
32	1,386	25	0.01	34,650	0.04	497	0:25	0
33	1,419	30	0.02	42,570	0.05	497	0:30	0
34	1,452	15	0.01	21,780	0.02	497	0:15	0
35	1,518	14	0.01	21,252	0.02	497	0:14	0
36	1,551	9	0.01	13,959	0.02	497	0:9	0
37	1,584	5	0.00	7,920	0.01	497	0:5	0
38	1,617	15	0.01	24,255	0.03	497	0:15	0
39	1,683	16	0.01	26,928	0.03	497	0:16	0
40	1,716	9	0.01	15,444	0.02	497	0:9	0
41	1,749	14	0.01	24,486	0.03	497	0:14	0
42	1,782	7	0.00	12,474	0.01	497	0:7	0
43	1,815	21	0.01	38,115	0.04	497	0:21	C
44	1,848	13	0.01	24,024	0.03	497	0:13	C
45	1,881	19	0.01	35,739	0.04	497	0:19	C
46	1,914	6	0.00	11,484	0.01	497	0:6	C
47	1,947	15	0.01	29,205	0.03	497	0:15	0
48	2,013	6	0.00	12,078	0.01	497	0:6	C
49	2,046	5	0.00	10,230	0.01	497	0:5	C
50	2,079	14	0.01	29,106	0.03	497	0:14	0
51	2,112	15	0.01	31,680	0.04	497	0:15	C
52	2,145	19	0.01	40,755	0.05	497	0:19	C
53	2,178	6	0.00	13,068	0.01	497	0:6	C
54	2,211	9	0.01	19,899	0.02	497	0:9	C
55	2,244	13	0.01	29,172	0.03	497	0:13	0
56	2,277	20	0.01	45,540	0.05	497	0:20	0
57		All applicants from	Serial no 28	to 56 for 1 (one) lot of	f 497 shares	497	3:427	1,491
58		85 Allottees from	m Serial no 2	to 57 Additional 1(or	ne) share	1	53:85	53
	TOTAL	171,204	100.00	88,409,970	100.00			815,488

#### . Allotment to Non-Institutional Bidders (more than ₹1.00 million) (After Rejections) (including ASBA Application

The Basis of Allotment to the Non-Institutional Bidders (more than ₹1 million), who have bid at the Offer Price of ₹ 428 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 166.94 times. The total number of Equity Shares allotted in this category is 1,630,976 Equity Shares to 3,294 successful applicants. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
1	2,343	107,620	95.30	252,153,660	92.61	495	11:377	1,554,300
2	2,376	1575	1.39	3,742,200	1.37	495	46:1575	22,770
3	2,409	396	0.35	953,964	0.35	495	12:396	5,940
4	2,442	190	0.17	463,980	0.17	495	6:190	2,970
5	2,475	550	0.49	1,361,250	0.50	495	16:550	7,920
121	6,963	1	0.00	6,963	0.00	495	0:1	0
122	7,062	2	0.00	14,124	0.01	495	0:2	0
123	7,095	3	0.00	21,285	0.01	495	0:3	0
124	7,128	3	0.00	21,384	0.01	495	0:3	0
125	7,161	1	0.00	7,161	0.00	495	0:1	0
271	70,059	1	0.00	70,059	0.03	495	0:1	0
272	70,092	1	0.00	70,092	0.03	495	0:1	0
273	116,853	1	0.00	116,853	0.04	495	0:1	0
274	222,189	1	0.00	222,189	0.08	495	0:1	0
275		All applicants from	n Serial no 30 t	o 274 for 1 (one) lot	of 495 shares	495	19:787	9,405
276		3,294 Allottees fr	om Serial no	1 to 275 Additional	1(one) share	1	13:96	446
	TOTAL	112,930	100.00	272,284,485	100.00			1,630,976

#### D. Allotment to QIBs

Allotment to QIBs, who have Bid at the Offer Price of ₹ 428 per Equity Share or above, has been done on a proportionate basis in consultation with the BSE. This category has been subscribed to the extent of 110.00 times of QIB Portion. As per the SEBI Regulations, Mutual Funds were Allotted 5% of the Equity Shares of QIB Portion available i.e., 244,647 Equity Shares and other QIBs and unsatisfied demand of Mutual Funds were Allotted the remaining available Equity Shares i.e., 4,648,284 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the QIB Portion is 4,892,931 Equity Shares, which were allotted to 162 successful QIB Investors. The category-wise details of the Basis of Allottment are as under:

Category	FI's/BANK's	MF's	IC's	NBFC's	AIF	FPC	VC's	Total
Allotment	1,306,389	554,352	189,917	905,592	784,266	1,152,415	-	4,892,931

#### E. Allotment to Anchor Investors

The Company, in consultation with the BRLMs, have allocated 7,339,395 Equity Shares to 24 Anchor Investors (through 31 Applications) at the Anchor Investor Offer Price of ₹ 428 per Equity Share in accordance with the SEBI Regulations. This represents 60% of the QIB Portion.

Category	FI's/BANK's	MF's	IC's	NBFC's	AIF	FPC	Others	Total
Allotment	-	4,368,771	233,946	-	-	2,736,678	-	7,339,395

The IPO Committee of our Company on Thursday, January 16, 2025 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and has allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Intimations and/ or notices have been dispatched to the address of the investors as registered with the depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Issue Account have been issued on Thursday, January 16, 2025 and payment to non-Syndicate brokers have been issued on Friday, January 17, 2025. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on Friday, January 17, 2025 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company has filed the Listing application with BSE and NSE on Friday, January 17, 2025. The Company has received listing and trading approval from BSE and NSE and the trading will commence on Monday, January 20, 2025.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

#### B. Allotment to Non-Institutional Bidders (More than ₹0.20 million Up to ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹0.20 million Up to ₹1.00 million), who have bid at the Offer Price of ₹ 428 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 108.41 times. The total number of Equity Shares allotted in this category is 815,488 Equity Shares to 1,647 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
1	495	162,343	94.82	80,359,785	90.89	495	1:104	773,190
2	528	1915	1.12	1,011,120	1.14	497	18:1915	8,946
3	561	655	0.38	367,455	0.42	497	6:655	2,982
4	594	475	0.28	282,150	0.32	497	5:475	2,485
5	627	214	0.13	134,178	0.15	497	2:214	994
6	660	625	0.37	412,500	0.47	497	6:625	2,982
7	693	273	0.16	189,189	0.21	497	3:273	1,491
8	726	263	0.15	190,938	0.22	497	3:263	1,491
9	759	110	0.06	83,490	0.09	497	1:110	497
10	792	115	0.07	91,080	0.10	497	1:115	497
11	825	192	0.11	158,400	0.18	497	2:192	994
12	858	72	0.04	61,776	0.07	497	1:72	497
13	891	102	0.06	90,882	0.10	497	1:102	497
14	924	128	0.07	118,272	0.13	497	1:128	497
15	957	117	0.07	111,969	0.13	497	1:117	497
16	990	876	0.51	867,240	0.98	497	8:876	3,976
17	1,023	87	0.05	89,001	0.10	497	1:87	497
18	1,056	66	0.04	69,696	0.08	497	1:66	497
19	1,089	65	0.04	70,785	0.08	497	1:65	497
20	1,122	81	0.05	90,882	0.10	497	1:81	497
21	1,155	1187	0.69	1,370,985	1.55	497	11:1187	5,467
22	1,188	133	0.08	158,004	0.18	497	1:133	497
23	1,320	88	0.05	116,160	0.13	497	1:88	497

#### INVESTORS PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Offer, **MUFG Intime India Private Limited** (Formerly Link Intime India Private Limited) at www.linkintime.co.in

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

# MUFG

Place: Mumbai Date: January 17, 2025

### MUFG INTIME INDIA PRIVATE LIMITED

(FORMERLY LINK INTIME INDIA PRIVATE LIMITED) C-101, 1st floor, 247 Park, L.B.S Marg, Vikhroli West, Mumbai - 400 083, Maharashtra, India Tel: +91 22 4918 6000/+91 8108114949 E-mail: laxmidental.ipo@linkintime.co.in Investor grievance e-mail: laxmidental.ipo@linkintime.co.in Website: www.linkintime.co.in Contact person: Shanti Gopal Krishnan SEBI Registration No.: INR000004058

For LAXMI DENTAL LIMITED	
On behalf of the Board of Directors	
Sd/-	
Nupur Joshi	
Company Secretary and Compliance Officer	

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF LAXMI DENTAL LIMITED.

LAXMI DENTAL LIMITED has filed the Prospectus with RoC and the Stock Exchanges on Thursday, January 16, 2025. The Prospectus is available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, the website of the Company at www.laxmidentallimited.com and on the websites of the Book Running Lead Managers ("BRLMs"), i.e. Nuvama Wealth Management Limited, Motilal Oswal Investment Advisors Limited and SBI Capital Markets Limited at www.nuvama.com, www.motilaloswalgroup.com and www.sbicaps.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "*Risk Factors*" beginning on page 37 of the Prospectus. Potential investors should not rely on the RHP filed with SEBI and the Stock Exchanges, and should instead rely on their own examination of our Company and the Offer, including the risks involved, for making any investment decision.

This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933 or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, the securities described in this announcement are not being offered or sold in the United States.